Top

Mariana Chavez Mac Gregor, M.D., MSC

Department of Health Services Research, Division of Cancer Prevention and Population Sciences

Present Title & Affiliation

Primary Appointment

Professor, Department of Health Services Research, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

2004	Netherlands Institute of Health and Sciences, Rotterdam, MSc, Clinical Epidemiology
2003	Universidad Nacional Autónoma de México, Facultad de Medicina, Mexico City, MEX, MD, Medicine

Postgraduate Training

2008-2011	Clinical Fellowship, Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
2006-2008	Clinical Residency, Internal Medicine, Barnes-Jewish Hospital/Washington University School of Medicine, St. Louis, MO
2005-2006	Clinical Internship, Internal Medicine, Barnes-Jewish Hospital/Washington University School of Medicine, St. Louis, MO

Board Certifications

2016	Medical Oncology (Mexican Board of Oncology)
2011	Medical Oncology
2008	Internal Medicine

Experience & Service

Academic Appointments

Associate Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - 2019

Associate Professor, Department of Health Services Research, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - 2019

Assistant Professor, Tenure Track, Department of Health Services Research, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, 2014 - 2017

Assistant Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2011 - 2014

Other Appointments/Responsibilities

Member, ASCO Ethics Committee, Alexandria, VA, 2021 - Present

Board of Directors, ASCO, Alexandria, VA, 2021 - Present

Member, ASCO's Equity Diversity and Inclusion (EDI) Strategic Priorities Task Force, Alexandria, VA, 2021 - Present

Ex-Officio Member, ASCO Guideline Methodology Subcommittee, Alexandria, VA, 2020 - 2021

Co-Chair, ASCO Breast Cancer Guidelines Advisory Group, Alexandria, VA, 2020 - 2021

Member, AJCC Breast Cancer Expert Panel for the 9th Version of AJCC Cancer Staging, 8888, 2020 - Present

Past Chair, ASCO Clinical Practice Guidelines, Alexandria, VA, 2019 - 2020

Chair, ASCO Guideline Methodology Subcommittee, Alexandria, VA, 2019 - 2020

Member, ASCO Stratified Resource Guidelines Advisory Group, Alexandria, VA, 2019 - Present

Liaison - Inbound, Cancer Committee, College of American Pathologists (CAP) Board of Governors, Northfield, IL, 2019 - 2021

Member, Chemotherapy for Women with Advanced HER-2 negative Breast Cancer Guideline Update, ASCO, Alexandria, VA, 2019 - 2019

Member, ASCO Women’s Networking Center Taskforce, Alexandria, VA, 2019 - Present

Member, ASCO eLearning Review Panel (Breast Cancer), Alexandria, VA, 2019 - Present

Chair, ASCO Clinical Practice Guidelines, Alexandria, VA, 2018 - 2019

Member, ASCO Leadership Development Program, Alexandria, VA, 2018 - 2019

Member, Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update, ASCO, Alexandria, VA, 2018 - 2019

Chair Elect, ASCO Clinical Practice Guidelines Committee, Alexandria, VA, 2017 - 2018

Member, Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Focused Update, ASCO, Alexandria, VA, 2017 - 2018

MD Anderson Physician Network Consultant, The University of Texas MD Anderson Cancer Center, Houston, TX, 2016 - Present

Member, SWOG CCDR Database Observational Study Working Group, unknown, 2015 - 2018

Member, ASCO Representative in the Consensus Guideline on margins for ductal carcinoma in situ cancer, ASCO/SSO/ASTRO, 2015 - 2016

Liaison Member, ASCO Quality of Care Committee, Alexandria, VA, 2014 - 2017

Member, ASCO Guideline Methodology Subcommittee, Alexandria, VA, 2014 - Present

Member, ASCO Clinical Practice Guideline Committee, Alexandria, VA, 2014 - 2017

Member, SWOG Cost-Effectiveness and Outcomes Committee, Portland, OR, 2013 - Present

Member, ASCO representative in the Consensus Guideline on margins for invasive breast cancer, SSO/ASTRO, 2013 - 2014

Member, National Breast Cancer Guideline Committee, Mexico, 2012 - Present

Member, SWOG Breast Committee, Portland, OR, 2011 - Present

Member, SWOG Breast Committee Working Group, Portland, OR, 2011 - Present

Medicine Chief Resident, John Cochran VA Medical Center, St. Louis, MO, 2007 - 2008

Study Coordinator, Departamento de Oncología, Instituto Nacional de Nutrición Salvador Zubirán, Mexico City, 2004 - 2005

Institutional Committee Activities

Member, Shared Resource Oversight Committee, 2020 - 2021

Member, Health Disparities Research Faculty Search Committee, 2018 - Present

Member, Radiation Oncology Division Head Search Committee, 2018 - 2019

Member, Health Services Research Faculty Search Committee, 2018 - Present

Medical Oncology Representative, Multidisciplinary Breast Evaluation Group Northwell, 2017 - 2018

Medical Oncology Advisor, Israelita Brasileira Hospital Albert Einstein Breast Tumor Board, 2017 - 2018

Medical Oncology Leader Liaison, MD Anderson Cancer Center Patient Advocate Initiative, 2017 - 2020

Member, Symptom Research Chair Search Committee, 2017 - 2017

Senator, Faculty Senate, 2016 - 2019

Member, Institutional Review Board IV, 2016 - 2018

Member, Department of Health Services Research Faculty Search Committee, 2015 - 2017

Member, Clinical Effectiveness Subcommittee (CE Subcommittee), 2015 - 2018

Nomination Committee, Charles A. LeMaistre Lecture, 2015 - 2017

Member, MD Anderson Cancer Center at Cooper (MDACCC) Relationship Committee, 2014 - Present

Member, Mexican-American Cohort Study Internal Advisory Board, 2014 - Present

Member, Multidisciplinary Breast Cancer Relationship Committee, 2014 - Present

Member, Clinical Research Committee 3, 2008 - 2012

Honors & Awards

2021	Fellow of the American Society of Clinical Oncology, The American Society of Clinical Oncology
2020	Faculty Honoree, President’s Recognition of Faculty Excellence,Clinical Quality Improvement, The University of Texas MD Anderson Cancer Center
2019	Top 10% Nationally in CAHPS measures related to patient experience and satisfaction, The University of Texas MD Anderson Cancer Center
2018	2018 Faculty Scholar Award, The University of Texas MD Anderson Cancer Center
2018	Academic Distinction for a Career in Breast Cancer Research, Best of ASCO Mexico
2017	Top 1% Nationally in CAHPS measures related to patient experience and satisfaction, The University of Texas MD Anderson Cancer Center
2015	Young Investigator Award, Multinational Association of Supportive Care in Cancer (MASCC)
2011	ASCO Cancer Foundation Merit Award, The Breast Cancer Symposium
2011	Achievement in Clinical Research Award, The Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
2011	Young Investigator Award, SWOG
2010	Allison and Brian Grove Endowed Fellowship for Breast Medical Oncology, The University of Texas MD Anderson Cancer Center
2010	ASCO Cancer Foundation Merit Award, The Breast Cancer Symposium
2010	AACR/ASCO Methods in Clinical Cancer Research Workshop, Vail, Colorado
2009	Allison and Brian Grove Endowed Fellowship for Breast Medical Oncology, The University of Texas MD Anderson Cancer Center
2009	AACR Minority Scholar, Susan G. Komen for the Cure
2009	ASCO Cancer Foundation Merit Award, The Breast Cancer Symposium
2008	Allison and Brian Grove Endowed Fellowship for Breast Medical Oncology, The University of Texas MD Anderson Cancer Center
2008	Kipnis-Daughaday Teaching Award, Washington University School of Medicine
2006	Clinical Scientist Training and Research Program, Barnes Jewish Hospital, Washington University School of Medicine, St. Louis, MO
2006	Best Poster Award, Mentors in Medicine Research Grant Scientific Symposium. Washington University School of Medicine
2004	NIHES Award, Erasmus University Rotterdam, University of Amsterdam, Utrecht University, University of Nijmegen, National Institute of Public Health and Environment, Netherlands Cancer Institute
2003	Merit-based Academic CONACYT Scholarship, The National Council for Science and Technology. Mexico
2002	Achievement Medical Student Award, Universidad Nacional Autónoma de México
2001	Academic Distinction, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico

Professional Memberships

American Association for Cancer Research

Associate Member, 2009 - Present

American Society of Clinical Oncology

Associate Member, 2008 - Present

Mexican Society of Senology

Member, 2001 - Present

Selected Publications

Peer-Reviewed Articles

Chavez Mac Gregor M, Lei X, Zhao H, Scheet P, Giordano SH. Evaluation of COVID-19 Mortality and Adverse Outcomes in US Patients With or Without Cancer. JAMA Oncol 2022 8(1):69-78. e-Pub 2021. PMID: 34709356.
Tamirisa N, Lei X, Caudle AS, Giordano SH, Zhao H, Chavez Mac Gregor M. Impact of SSO-ASTRO "No Ink on Tumor" Guidelines on Reexcision Rates among Older Breast Cancer Patients. Ann Surg Oncol 28(7):3703-3713, 2021. e-Pub 2020. PMID: 33225394.
Zhao H, Lei X, Niu J, Zhang N, Duan Z, Chavez Mac Gregor M, Giordano SH. Prescription Patterns, Initiation, and 5-Year Adherence to Adjuvant Hormonal Therapy Among Commercially Insured Patients With Breast Cancer. JCO Oncol Pract 17(6):OP2000248, 2021. e-Pub 2021. PMID: 33596096.
Denduluri N, Somerfield MR, Chavez Mac Gregor M, Comander AH, Dayao Z, Eisen A, Freedman RA, Gopalakrishnan R, Graff SL, Hassett MJ, King TA, Lyman GH, Maupin GR, Nunes R, Perkins CL, Telli ML, Trudeau ME, Wolff AC, Giordano SH. Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update. J Clin Oncol 39(6):JCO2002510, 2021. e-Pub 2020. PMID: 33079579.
Lim B, Song J, Ibrahim NK, Koenig KB, Chavez Mac Gregor M, Ensor JE, Gomez JS, Krishnamurthy S, Caudle AS, Shaitelman SF, Whitman GJ, Valero V. A Randomized Phase II Study of Sequential Eribulin Versus Paclitaxel Followed by FAC/FEC as Neoadjuvant Therapy in Patients with Operable HER2-Negative Breast Cancer. Oncologist 26(2):e230-e240, 2021. e-Pub 2020. PMID: 33140515.
Bardia A, Modi S, Oliveira M, Cortés J, Campone M, Ma BBY, Dirix LY, Weise A, Hewes B, Diaz-Padilla I, Han Y, Deshpande P, Samant T, Rodriguez Lorenc CK, He W, Su F, Chavez Mac Gregor M. Phase 1b Dose Escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women With HR+, HER2- Advanced Breast Cancer. Clin Cancer Res 26(24):6417-6428, 2020. e-Pub 2020. PMID: 32998962.
Sharma M, Duan Z, Zhao H, Giordano SH, Chavez Mac Gregor M. Real-World Patterns of Everolimus Use in Patients with Metastatic Breast Cancer. Oncologist 25(11):937-942, 2020. e-Pub 2020. PMID: 32476216.
Sharabi SE, Baumann DP, Selber JC, Killon E, Mericli AF, Liu J, Caudle AS, Smith BD, Chavez Mac Gregor M, Schaverien MV. Complications of Contralateral Prophylactic Mastectomy: Do They Delay Adjuvant Therapy?. Plast Reconstr Surg 146(5):945-953, 2020. PMID: 33136936.
Smith-Graziani D, Lei X, Giordano SH, Zhao H, Karuturi M, Chavez Mac Gregor M. Delayed initiation of adjuvant chemotherapy in older women with breast cancer. Cancer Med 9(19):6961-6971, 2020. e-Pub 2020. PMID: 32767723.
de Melo Gagliato D, Lei X, Giordano SH, Valero V, Barcenas CH, Hortobagyi GN, Chavez Mac Gregor M. Impact of delayed neoadjuvant systemic chemotherapy on overall survival among breast cancer patients. Oncologist 25(9):749-757, 2020. e-Pub 2020. PMID: 32431013.
Suarez-Almazor ME, Herrera R, Lei X, Chavez Mac Gregor M Zhao H, Giordano SH. Survival in older women with early stage breast cancer receiving low-dose bisphosphonates or denosumab. Cancer 126(17):3929-3938, 2020. e-Pub 2020. PMID: 32573777.
Cacho-Díaz B, Salmerón-Moreno K, Alvarez-Alvarez A, Mendoza-Olivas LG, Alvarado-Miranda A, Villarreal-Garza C, Reynoso-Noverón N, Chavez Mac Gregor M, Meneses-García AA. Identification of risk factors for central nervous system metastasis in patients with breast cancer with neurologic symptoms. Cancer 126(15):3456-3463, 2020. e-Pub 2020. PMID: 32453447.
Kantor O, Niu J, Zhao H, Giordano SH, Hunt KK, King TA, Mittendorf EA, Chavez Mac Gregor M. Comparative Analysis of Proposed Strategies for Incorporating Biologic Factors into Breast Cancer Staging. Ann Surg Oncol 27(7):2229-2237, 2020. e-Pub 2020. PMID: 31916091.
Kogawa T, Fujii T, Wu J, Harano K, Fouad TM, Liu DD, Shen Y, Masuda H, Krishnamurthy S, Chavez Mac Gregor M, Lim B, Murthy RK, Valero V, Tripathy D, Ueno NT. Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without Trastuzumab. Oncologist 25(6):e909-e919, 2020. e-Pub 2020. PMID: 32003919.
Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, Hayes DF, Lakhani SR, Chavez Mac Gregor M, Perlmutter J, Perou CM, Regan MM, Rimm DL, Symmans WF, Torlakovic EE, Varella L, Viale G, Weisberg TF, McShane LM, Wolff AC. Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update. Arch Pathol Lab Med 144(5):545-563, 2020. e-Pub 2020. PMID: 31928354.
Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, Hayes DF, Lakhani SR, Chavez Mac Gregor M, Perlmutter J, Perou CM, Regan MM, Rimm DL, Symmans WF, Torlakovic EE, Varella L, Viale G, Weisberg TF, McShane LM, Wolff AC. Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. J Clin Oncol 38(12):JCO1902309, 2020. e-Pub 2020. PMID: 31928404.
Shah MA, Oliver TK, Peterson DE, Einhaus K, Schneider BJ, Denduluri N, Chavez Mac Gregor M. ASCO Clinical Practice Guideline Endorsements and Adaptations. J Clin Oncol 38(8):JCO1902839, 2020. e-Pub 2019. PMID: 31841361.
Le Du F, Fujii T, Kida K, Davis DW, Park M, Liu DD, Wu W, Chavez Mac Gregor M, Barcenas CH, Valero V, Tripathy D, Reuben JM, Ueno NT. EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStream® in patients with breast cancer treated with primary systemic therapy. PLoS One 15(3):e0229903, 2020. e-Pub 2020. PMID: 32214335.
Yi M, Lin H, Bedrosian I, Shen Y, Hunt KK, Chavez Mac Gregor M, King TA, Mittendorf EA. Staging for Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: Utility of Incorporating Biologic Factors. Ann Surg Oncol 27(2):359-366, 2020. e-Pub 2019. PMID: 31667721.
Adamson K, Chavez Mac Gregor M, Caudle A, Smith B, Baumann D, Liu J, Schaverien M. Neoadjuvant Chemotherapy does not Increase Complications in Oncoplastic Breast-Conserving Surgery. Ann Surg Oncol 26(9):2730-2737, 2019. e-Pub 2019. PMID: 31037439.
Xing Y, Lin NU, Maurer MA, Chen H, Mahvash A, Sahin A, Akcakanat A, Li Y, Abramson V, Litton J, Chavez Mac Gregor M, Valero V, Piha-Paul SA, Hong D, Do KA, Tarco E, Riall D, Eterovic AK, Wulf GM, Cantley LC, Mills GB, Doyle LA, Winer E, Hortobagyi GN, Gonzalez-Angulo AM, Meric-Bernstam F. Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. Breast Cancer Res 21(1):78, 2019. e-Pub 2019. PMID: 31277699.
Avila J, Jupiter D,Chavez Mac Gregor M, de Oliveira C, Kaul S. High-Cost Hospitalizations Among Elderly Patients With Cancer. J Oncol Pract 15(5):e447-e457, 2019. e-Pub 2019. PMID: 30946640.
Yam C, Esteva FJ, Patel MM, Raghavendra AS, Ueno NT, Moulder SL, Hess KR, Shroff GS, Hodge S, Koenig KH, Chavez Mac Gregor M, Griner RL, Yeung SJ, Hortobagyi GN, Valero V. Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study. Invest New Drugs 37(2):345-351, 2019. e-Pub 2019. PMID: 30610588.
Sharma M, Vadhariya A, Chikermane S, Gopinathan S, Chavez Mac Gregor M, Giordano SH, Johnson ML, Holmes HM. Clinical Outcomes Associated with Drug-Drug Interactions of Oral Chemotherapeutic Agents: A Comprehensive Evidence-Based Literature Review. Drugs Aging 36(4):341-354, 2019. e-Pub 2019. PMID: 30714077.
Pal SK, Miller MJ, Agarwal N, Chang SM, Chavez Mac Gregor M, Cohen E, Cole S, Dale W, Magid Diefenbach CS, Disis ML, Dreicer R, Graham DL, Henry NL, Jones J, Keedy V, Klepin HD, Markham MJ, Mittendorf EA, Rodriguez-Galindo C, Sabel MS, Schilsky RL, Sznol M, Tap WD, Westin SN, Johnson BE. Clinical Cancer Advances 2019: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol 37(10):JCO1802037, 2019. e-Pub 2019. PMID: 30702028.
Wong Y, Raghavendra AS, Hatzis C, Irizarry JP, Vega T, Horowitz N, Barcenas CH, Chavez Mac Gregor M, Valero V, Tripathy D, Pusztai L, Murthy RK. Long-Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2-Targeted Therapy. Oncologist 24(3):313-318, 2019. e-Pub 2018. PMID: 30139836.
Hwang JP, Huang D, Vierling JM, Suarez-Almazor ME, Shih YT, Chavez Mac Gregor M, Duan Z, Giordano SH, Hershman DL, Fisch MJ, Cantor SB. Cost-Effectiveness Analysis of Hepatitis B Virus Screening and Management in Patients With Hematologic or Solid Malignancies Anticipating Immunosuppressive Cancer Therapy. JCO Clin Cancer Inform 3:1-12, 2019. PMID: 30892921.
Taylor JS, Zhang N, Rajan SS, Chavez Mac Gregor M, Zhao H, Niu J, Meyer LA, Ramondetta LM, Bodurka DC, Lairson DR, Giordano SH. How we use hospice: Hospice enrollment patterns and costs in elderly ovarian cancer patients. Gynecol Oncol 152(3):452-458, 2019. PMID: 30876488.
Tadros AB, Smith BD, Shen Y, Lin H, Krishnamurthy S, Lucci A, Barcenas CH, Hwang RF, Rauch G, Santiago L, Strom EA, DeSnyder SM, Yang WT, Black DM, Albarracin CT, Chavez Mac Gregor M, Hunt KK, Kuerer HM. Ductal Carcinoma In Situ and Margins <2mm: Contemporary Outcomes With Breast Conservation. Ann Surg 269(1):150-157, 2019. e-Pub 2017. PMID: 28742682.
Murthy RK, Raghavendra AS, Hess KR, Fujii T, Lim B, Barcenas CH, Zhang H, Chavez Mac Gregor M, Mittendorf EA, Litton JK, Giordano SH, Thompson AM, Valero V, Moulder SL, Tripathy D, Ueno NT. Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution Experience. Clin Breast Cancer 18(6):e1283-e1288, 2018. e-Pub 2018. PMID: 30077429.
Kehl KL, Niu J, Chavez Mac Gregor M, Giordano SH. Hospitalization by cytotoxic chemotherapy regimen among older women with stage IV breast cancer. Cancer 124(24):4685-4691, 2018. e-Pub 2018. PMID: 30264853.
Basho RK, Yam C, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Valero V, Albarracin C, Litton JK, Chavez Mac Gregor M, Hong D, Kurzrock R, Hortobagyi GN, Janku F, Moulder SL. Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer. Oncologist 23(11):1300-1309, 2018. e-Pub 2018. PMID: 30139837.
DeSnyder SM, Hunt KK, Dong W, Smith BD, Moran MS, Chavez Mac Gregor M, Shen Y, Kuerer HM, Lucci A. American Society of Breast Surgeons' Practice Patterns After Publication of the SSO-ASTRO-ASCO DCIS Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation. Ann Surg Oncol 25(10):2965-2974, 2018. e-Pub 2018. PMID: 29987598.
Chavez Mac Gregor M, Lei X, Zhao H, van Poznak C, Giordano SH. Use of bone-modifying agents (BMA) and osteonecrosis of the jaw (ONJ) among older patients with metastatic breast cancer (BC). Ann Oncol 29 Suppl 8:viii115, 2018. PMID: 32136136.
Namuche F, Ruiz RE, Morante Cruz ZD, Urrunaga D, Ziegler G, Mantilla R, Leon Rivera M, Chavez Mac Gregor M, Gomez Moreno HL. Oncotype Dx results in patients =40 years: Does age matter? New insights. Ann Oncol 29 Suppl 8:viii67-viii68, 2018. PMID: 32137832.
Giordano SH, Duan Z, Zhao H, Hwang J, Chavez Mac Gregor M. Hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) screening prior to chemotherapy initiation among patients with solid tumors. Ann Oncol 29 Suppl 8:viii633, 2018. PMID: 32137713.
Denduluri N, Chavez Mac Gregor M, Telli ML, Eisen A, Graff SL, Hassett MJ, Holloway JN, Hurria A, King TA, Lyman GH, Partridge AH, Somerfield MR, Trudeau ME, Wolff AC, Giordano SH. Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update. J Clin Oncol 36(23):JCO2018788604, 2018. e-Pub 2018. PMID: 29787356.
Cacho-Díaz B, Spínola-Maroño H, Arrieta VA, Granados-García M, Wegman-Ostrosky T, Mendoza-Olivas LG, Chavez Mac Gregor M. Diagnosis of brain metastases in breast cancer patients resulting from neurological symptoms. Clin Neurol Neurosurg 173:61-64. e-Pub 2018. PMID: 30086430.
Henry ML, Niu J, Zhang N, Giordano SH, Chavez Mac Gregor M. Cardiotoxicity and Cardiac Monitoring Among Chemotherapy-Treated Breast Cancer Patients. JACC Cardiovasc Imaging 11(8):1084-1093, 2018. PMID: 30092967.
Unger JM, Moseley A, Symington B, Chavez Mac Gregor M, Ramsey SD, Hershman DL. Geographic Distribution and Survival Outcomes for Rural Patients With Cancer Treated in Clinical Trials. JAMA Netw Open 1(4):e181235, 2018. e-Pub 2018. PMID: 30646114.
Al-Sukhun S, Temin S, Chavez Mac Gregor M, Denduluri N, Oliver TK, Pyle D, Shah MA, Gralow J. ASCO Resource-Stratified Guidelines: Methods and Opportunities. J Glob Oncol(4):1-8, 2018. PMID: 30110223.
Kuerer HM, Rauch GM, Krishnamurthy S, Adrada BE, Caudle AS, DeSnyder SM, Black DM, Santiago L, Hobbs BP, Lucci A, Gilcrease M, Hwang RF, Candelaria RP, Chavez Mac Gregor M, Smith BD, Arribas E, Moseley T, Teshome M, Miggins MV, Valero V, Hunt KK, Yang WT. A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy. Ann Surg 267(5):946-951, 2018. e-Pub 2017. PMID: 28549010.
Chavez Mac Gregor M, Unger JM, Moseley A, Ramsey SD, Hershman DL. Survival by Hispanic ethnicity among patients with cancer participating in SWOG clinical trials. Cancer 124(8):1760-1769, 2018. e-Pub 2018. PMID: 29370458.
Rosenstock AS, Niu J, Giordano SH, Zhao H, Wolff AC, Chavez Mac Gregor M. Acute myeloid leukemia and myelodysplastic syndrome after adjuvant chemotherapy: A population-based study among older breast cancer patients. Cancer 124(5):899-906, 2018. e-Pub 2017. PMID: 29236294.
Zhao H, Zhang N, Ho V, Ding M, He W, Niu J, Yang M, Du XL, Zorzi D, Chavez Mac Gregor M, Giordano SH. Adherence to treatment guidelines and survival for older patients with stage II or III colon cancer in Texas from 2001 through 2011. Cancer 124(4):679-687, 2018. e-Pub 2017. PMID: 29140558.
Weiss A, Chavez Mac Gregor M, Lichtensztajn DY, Yi M, Tadros A, Hortobagyi GN, Giordano SH, Hunt KK, Mittendorf EA. Validation Study of the American Joint Committee on Cancer Eighth Edition Prognostic Stage Compared With the Anatomic Stage in Breast Cancer. JAMA Oncol 4(2):203-209, 2018. e-Pub 2017. PMID: 29222540.
Cortés J, Im SA, Holgado E, Perez-Garcia JM, Schmid P, Chavez Mac Gregor M. The next era of treatment for hormone receptor-positive, HER2-negative advanced breast cancer: Triplet combination-based endocrine therapies. Cancer Treat Rev 61:53-60, 2017. e-Pub 2017. PMID: 29100169.
Mittendorf EA, Chavez Mac Gregor M, Vila J, Yi M, Lichtensztajn DY, Clarke CA, Giordano SH, Hunt KK. Bioscore: A Staging System for Breast Cancer Patients that Reflects the Prognostic Significance of Underlying Tumor Biology. Ann Surg Oncol 24(12):3502-3509, 2017. e-Pub 2017. PMID: 28726077.
Chavez Mac Gregor M, Mittendorf EA, Clarke CA, Lichtensztajn DY, Hunt KK, Giordano SH. Incorporating Tumor Characteristics to the American Joint Committee on Cancer Breast Cancer Staging System. Oncologist 22(11):1292-1300, 2017. e-Pub 2017. PMID: 28592619.
Shih YT, Xu Y, Chavez Mac Gregor M, Guadagnolo BA, Smith BD, Giordano SH. Association Between Quality of Care for Breast Cancer and Health Insurance Exchange Coverage: An Analysis of Use of Radiation Therapy After Breast-Conserving Surgery. JAMA Oncol 3(10):1425-1426, 2017. e-Pub 2017. PMID: 28570719.
Hwang JP, Suarez-Almazor ME, Cantor SB, Barbo A, Lin HY, Ahmed S, Chavez Mac Gregor M, Donato-Santana C, Eng C, Ferrajoli A, Fisch MJ, McLaughlin P, Simon GR, Rondon G, Shpall EJ, Lok AS. Impact of the timing of hepatitis B virus identification and anti-hepatitis B virus therapy initiation on the risk of adverse liver outcomes for patients receiving cancer therapy. Cancer 123(17):3367-3376, 2017. e-Pub 2017. PMID: 28518219.
Barcenas CH, Raghavendra A, Sinha AK, Syed MP, Hsu L, Patangan MG, Chavez Mac Gregor M, Shen Y, Hortobagyi GH, Valero V, Giordano SH, Ueno NT, Tripathy D. Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay. Cancer 123(13):2422-2431, 2017. e-Pub 2017. PMID: 28199747.
Wu X, Ye Y, Barcenas CH, Chow WH, Meng QH, Chavez Mac Gregor M, Hildebrandt MA, Zhao H, Gu X, Deng Y, Wagar E, Esteva FJ, Tripathy D, Hortobagyi GN. Personalized Prognostic Prediction Models for Breast Cancer Recurrence and Survival Incorporating Multidimensional Data. J Natl Cancer Inst 109(7), 2017. PMID: 28376179.
Zhao H, Hei N, Wu Y, Chan W, Lei X, Cameron C, Chang S, Chavez Mac Gregor M, Giordano SH. Initiation of and adherence to tamoxifen and aromatase inhibitor therapy among elderly women with ductal carcinoma in situ. Cancer 123(6):940-947, 2017. e-Pub 2016. PMID: 27780311.
Basho RK, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Herbrich SM, Valero V, Albarracin C, Litton JK, Chavez Mac Gregor M, Ibrahim NK, Murray JL, Koenig KB, Hong D, Subbiah V, Kurzrock R, Janku F, Moulder SL. Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab. JAMA Oncol 3(4):509-515, 2017. e-Pub 2016. PMID: 27893038.
Vila J, Teshome M, Tucker SL, Woodward WA, Chavez Mac Gregor M, Hunt KK, Mittendorf EA. Combining Clinical and Pathologic Staging Variables Has Prognostic Value in Predicting Local-regional Recurrence Following Neoadjuvant Chemotherapy for Breast Cancer. Ann Surg 265(3):574-580, 2017. e-Pub 2016. PMID: 27735826.
Candelaria RP, Huang ML, Adrada BE, Bassett R, Hunt KK, Kuerer HM, Smith BD, Chavez Mac Gregor M, Yang WT. Incremental Cancer Detection of Locoregional Restaging with Diagnostic Mammography Combined with Whole-Breast and Regional Nodal Ultrasound in Women with Newly Diagnosed Breast Cancer. Acad Radiol S1076-6332(16):30396-8, 2017. PMID: 27955877.
Fujii T, Kogawa T, Wu J, Sahin AA, Liu DD, Chavez Mac Gregor M, Giordano SH, Raghavendra A, Murthy RK, Tripathy D, Shen Y, Yamal JM, Ueno NT. Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy. Br J Cancer 116(4):509-514, 2017. e-Pub 2017. PMID: 28081544.
Tuttle TM, Barrio AV, Klimberg VS, Giuliano AE, Chavez Mac Gregor M, Buum HA, McMasters KM. Guidelines for Guidelines: An Assessment of the American Society of Breast Surgeons Contralateral Prophylactic Mastectomy Consensus Statement. Ann Surg Oncol 24(1):1-2, 2017. e-Pub 2016. PMID: 27783164.
Kuerer HM, Smith BD, Chavez Mac Gregor M, Albarracin C, Barcenas CH, Santiago L, Edgerton ME, Rauch GM, Giordano SH, Sahin A, Krishnamurthy S, Woodward W, Tripathy D, Yang WT, Hunt KK. DCIS Margins and Breast Conservation: MD Anderson Cancer Center Multidisciplinary Practice Guidelines and Outcomes. J Cancer 8(14):2653-2662, 2017. e-Pub 2017. PMID: 28928852.
Morrow M, Van Zee KJ, Solin LJ, Houssami N, Chavez Mac Gregor M, Harris JR, Horton J, Hwang S, Johnson PL, Marinovich ML, Schnitt SJ, Wapnir I, Moran MS. Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma In Situ. J Clin Oncol 34(33):4040-4046, 2016. e-Pub 2016. PMID: 27528719.
Morrow M, Van Zee KJ, Solin LJ, Houssami N, Chavez Mac Gregor M, Harris JR, Horton J, Hwang S, Johnson PL, Marinovich ML, Schnitt SJ, Wapnir I, Moran MS. Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery with Whole-Breast Irradiation in Ductal Carcinoma In Situ. Ann Surg Oncol 23(12):3801-3810, 2016. e-Pub 2016. PMID: 27527714.
Stauder MC, Caudle AS, Allen PK, Shaitelman SF, Smith BD, Hoffman KE, Buchholz TA, Chavez Mac Gregor M, Hunt KK, Meric-Bernstam F, Woodward WA. Outcomes of Post Mastectomy Radiation Therapy in Patients Receiving Axillary Lymph Node Dissection After Positive Sentinel Lymph Node Biopsy. Int J Radiat Oncol Biol Phys 96(3):637-44, 2016. e-Pub 2016. PMID: 27681760.
Giordano SH, Niu J, Chavez Mac Gregor M, Zhao H, Zorzi D, Shih YT, Smith BD, Shen C. Estimating regimen-specific costs of chemotherapy for breast cancer: Observational cohort study. Cancer 122(22):3447-3455, 2016. e-Pub 2016. PMID: 27723214.
Basho RK, de Melo Gagliato D, Ueno NT, Wathoo C, Chen H, Shariati M, Wei C, Alvarez RH, Moulder SL, Sahin AA, Roy-Chowdhuri S, Chavez Mac Gregor M, Litton JK, Valero V, Luthra R, Zeng J, Shaw KR, Mendelsohn J, Mills GB, Tripathy D, Meric-Bernstam F. Clinical outcomes based on multigene profiling in metastatic breast cancer patients. Oncotarget 7(47):76362-76373, 2016. e-Pub 2016. PMID: 27806348.
Vila J, Mittendorf EA, Farante G, Bassett RL, Veronesi P, Galimberti V, Peradze N, Stauder MC, Chavez Mac Gregor M, Litton JF, Huo L, Kuerer HM, Hunt KK, Caudle AS. Nomograms for Predicting Axillary Response to Neoadjuvant Chemotherapy in Clinically Node-Positive Patients with Breast Cancer. Ann Surg Oncol 23(11):3501-9, 2016. e-Pub 2016. PMID: 27216742.
Morrow M, Van Zee KJ, Solin LJ, Houssami N, Chavez Mac Gregor M, Harris JR, Horton J, Hwang S, Johnson PL, Marinovich ML, Schnitt SJ, Wapnir I, Moran MS. Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma in Situ. Pract Radiat Oncol 6(5):287-95, 2016. e-Pub 2016. PMID: 27538810.
Cata JP, Chavez Mac Gregor M, Valero V, Black W, Black DM, Goravanchi F, Ifeanyi IC, Hernandez M, Rodriguez-Restrepo A, Gottumukkala V. The Impact of Paravertebral Block Analgesia on Breast Cancer Survival After Surgery. Reg Anesth Pain Med 41(6):696-703. e-Pub 2016. PMID: 27685344.
Harano K, Lei X, Gonzalez-Angulo AM, Murthy RK, Valero V, Mittendorf EA, Ueno NT, Hortobagyi GN, Chavez Mac Gregor M. Clinicopathological and surgical factors associated with long-term survival in patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat 159(2):367-74, 2016. e-Pub 2016. PMID: 27522517.
Cleeland C, von Moos R, Walker MS, Wang Y, Gao J, Chavez Mac Gregor M, Liede A, Arellano J, Balakumaran A, Qian Y. Burden of symptoms associated with development of metastatic bone disease in patients with breast cancer. Support Care Cancer 24(8):3557-65, 2016. e-Pub 2016. PMID: 27022965.
Mittendorf EA, Vila J, Tucker SL, Chavez Mac Gregor M, Smith BD, Symmans WF, Sahin AA, Hortobagyi GN, Hunt KK. The Neo-Bioscore Update for Staging Breast Cancer Treated With Neoadjuvant Chemotherapy: Incorporation of Prognostic Biologic Factors Into Staging After Treatment. JAMA Oncol 2(7):929-36, 2016. e-Pub 2016. PMID: 26986538.
Elting LS, Xu Y, Chavez Mac Gregor M, Giordano SH. Granulocyte growth factor use in elderly patients with non-Hodgkin's lymphoma in the United States: adherence to guidelines and comparative effectiveness. Support Care Cancer 24(6):2695-706, 2016. e-Pub 2016. PMID: 26797253.
Rosenstock AS, Lei X, Tripathy D, Hortobagyi GN, Giordano SH, Chavez Mac Gregor M. Short-term mortality in older patients treated with adjuvant chemotherapy for early-stage breast cancer. Breast Cancer Res Treat 157(2):339-50, 2016. e-Pub 2016. PMID: 27146586.
Sanford RA, Lei X, Barcenas CH, Mittendorf EA, Caudle AS, Valero V, Tripathy D, Giordano SH, Chavez Mac Gregor M. Impact of Time from Completion of Neoadjuvant Chemotherapy to Surgery on Survival Outcomes in Breast Cancer Patients. Ann Surg Oncol 23(5):1515-21, 2016. e-Pub 2015. PMID: 26678405.
Caudle AS, Yang WT, Krishnamurthy S, Mittendorf EA, Black DM, Gilcrease MZ, Bedrosian I, Hobbs BP, DeSnyder SM, Hwang RF, Adrada BE, Shaitelman SF, Chavez Mac Gregor M, Smith BD, Candelaria RP, Babiera GV, Dogan BE, Santiago L, Hunt KK, Kuerer HM. Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection. J Clin Oncol 34(10):1072-8, 2016. e-Pub 2016. PMID: 26811528.
Chavez Mac Gregor M, Clarke CA, Lichtensztajn DY, Giordano SH. Delayed Initiation of Adjuvant Chemotherapy among Patients with Breast Cancer. JAMA Oncol 2(3):322-9, 2016. PMID: 26659132.
Kogawa T, Fouad TM, Liu DD, Wu J, Shen Y, Masuda H, Fujii T, Chavez Mac Gregor M, Alvarez RH, Hortobagyi GN, Valero V, Ueno NT. High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer. Oncologist 21(1):21-7, 2016. e-Pub 2015. PMID: 26659222.
Roy-Chowdhuri S, de Melo Gagliato D, Routbort MJ, Patel KP, Singh RR, Broaddus R, Lazar AJ, Sahin A, Alvarez RH, Moulder S, Wheler JJ, Janku F, Gonzalez-Angulo AM, Chavez Mac Gregor M, Valero V, Ueno NT, Mills G, Mendelsohn J, Yao H, Aldape K, Luthra R, Meric-Bernstam F. Multigene Clinical Mutational Profiling of Breast Carcinoma Using Next-Generation Sequencing. Am J Clin Pathol 144(5):713-21, 2015. PMID: 26486734.
Chaudry M, Lei X, Gonzalez-Angulo AM, Mittendorf EA, Valero V, Tripathy D, Hortobagyi GN, Chavez Mac Gregor M. Recurrence and survival among breast cancer patients achieving a pathological complete response to neoadjuvant chemotherapy. Breast Cancer Res Treat 153(2):417-23, 2015. e-Pub 2015. PMID: 26272743.
Chavez Mac Gregor M, Niu J, Zhang N, Elting LS, Smith BD, Banchs J, Hortobagyi GN, Giordano SH. Cardiac Monitoring During Adjuvant Trastuzumab-Based Chemotherapy Among Older Patients with Breast Cancer. J Clin Oncol 33(19):2176-83, 2015. e-Pub 2015. PMID: 25964256.
Subbiah IM, Lei X, Weinberg JS, Sulman EP, Chavez Mac Gregor M, Tripathy D, Gupta R, Varma A, Chouhan J, Guevarra RP, Valero V, Gilbert MR, Gonzalez-Angulo AM. Validation and Development of a Modified Breast Graded Prognostic Assessment as a Tool for Survival in Patients with Breast Cancer and Brain Metastases. J Clin Oncol 33(20):2239-45, 2015. e-Pub 2015. PMID: 25987700.
Fouad TM, Kogawa T, Liu DD, Shen Y, Masuda H, El-Zein R, Woodward WA, Chavez Mac Gregor M, Alvarez RH, Arun B, Lucci A, Krishnamurthy S, Babiera G, Buchholz TA, Valero V, Ueno NT. Overall survival differences between patients with inflammatory and non-inflammatory breast cancer presenting with distant metastasis at diagnosis. Breast Cancer Res Treat 152(2):407-16, 2015. e-Pub 2015. PMID: 26017070.
Fouad TM, Kogawa T, Liu DD, Shen Y, Masuda H, El-Zein R, Woodward WA, Chavez Mac Gregor M, Alvarez RH, Arun B, Lucci A, Krishnamurthy S, Babiera G, Buchholz TA, Valero V, Ueno NT. Erratum to: Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis. Breast Cancer Res Treat 152(2):417, 2015. PMID: 26092296.
Parinyanitikul N, Lei X, Chavez Mac Gregor M, Liu S, Mittendorf EA, Litton JK, Woodward W, Zhang AH, Hortobagyi GN, Valero V, Meric-Bernstam F, Gonzalez-Angulo AM. Receptor Status Change From Primary to Residual Breast Cancer After Neoadjuvant Chemotherapy and Analysis of Survival Outcomes. Clin Breast Cancer 15(2):153-60, 2015. e-Pub 2014. PMID: 25454687.
Liu S, Meric-Bernstam F, Parinyanitikul N, Wang B, Eterovic AK, Zheng X, Gagea M, Chavez Mac Gregor M, Ueno NT, Lei X, Zhou W, Nair L, Tripathy D, Brown PH, Hortobagyi GN, Chen K, Mendelsohn J, Mills GB, Gonzalez-Angulo AM. Functional consequence of the MET-T1010I polymorphism in breast cancer. Oncotarget 6(5):2604-14, 2015. e-Pub 2014. PMID: 25605252.
Gonzalez-Angulo AM, Parinyanitikul N, Lei X, Mittendorf EA, Zhang H, Valero V, Hunt KK, Hortobagyi GN, Chavez Mac Gregor M. Effect of adjuvant trastuzumab among patients treated with anti-HER2-based neoadjuvant therapy. Br J Cancer 112(4):630-5, 2015. e-Pub 2015. PMID: 25584488.
Rueth NM, Black DM, Limmer AR, Gabriel E, Huo L, Fornage BD, Dogan BE, Chavez MacGregor M, Yi M, Hunt KK, Strom EA. Breast conservation in the setting of contemporary multimodality treatment provides excellent outcomes for patients with occult primary breast cancer. Ann Surg Oncol 22(1):90-5, 2015. e-Pub 2014. PMID: 25249256.
Kogawa T, Fouad TM, Wei C, Masuda H, Kai K, Fujii T, El-Zein R, Chavez Mac Gregor M, Litton JK, Brewster A, Alvarez RH, Hortobagyi GN, Valero V, Theriault R, Ueno NT. Association of Body Mass Index Changes during Neoadjuvant Chemotherapy with Pathologic Complete Response and Clinical Outcomes in Patients with Locally Advanced Breast Cancer. J Cancer 6(4):310-8, 2015. e-Pub 2015. PMID: 25767600.
Mittendorf EA, Caudle AS, Yang W, Krishnamurthy S, Shaitelman S, Chavez Mac Gregor M, Woodward WA, Bedrosian I, Kuerer HM, Hunt KK. Implementation of the American college of surgeons oncology group z1071 trial data in clinical practice: is there a way forward for sentinel lymph node dissection in clinically node-positive breast cancer patients treated with neoadjuvant chemotherapy?. Ann Surg Oncol 21(8):2468-73, 2014. e-Pub 2014. PMID: 24841348.
Moran MS, Schnitt SJ, Giuliano AE, Harris JR, Khan SA, Horton J, Klimberg S, Chavez Mac Gregor M, Freedman G, Houssami N, Johnson PL, Morrow M, Society of Surgical Oncology, American Society for Radiation Oncology. Society of Surgical Oncology-American Society for Radiation Oncology Consensus Guideline on Margins for Breast-Conserving Surgery with Whole-Breast Irradiation in Stages I and II Invasive Breast Cancer. J Clin Oncol 32(14):1507-15, 2014. e-Pub 2014. PMID: 24516019.
Gagliato D de M, Gonzalez-Angulo AM, Lei X, Theriault RL, Giordano SH, Valero V, Hortobagyi GN, Chavez Mac Gregor M. Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer. J Clin Oncol 32(8):735-44, 2014. e-Pub 2014. PMID: 24470007.
Moran MS, Schnitt SJ, Giuliano AE, Harris JR, Khan SA, Horton J, Klimberg S, Chavez Mac Gregor M, Freedman G, Houssami N, Johnson PL, Morrow M. Society of Surgical Oncology-American Society for Radiation Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stages I and II Invasive Breast Cancer. Int J Radiat Oncol Biol Phys 88(3):553-64, 2014. PMID: 24521674.
Moran MS, Schnitt SJ, Giuliano AE, Harris JR, Khan SA, Horton J, Klimberg S, Chavez Mac Gregor M, Freedman G, Houssami N, Johnson PL, Morrow M. Society of Surgical Oncology-American Society for Radiation Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stages I and II Invasive Breast Cancer. Ann Surg Oncol 21(3):704-16, 2014. e-Pub 2014. PMID: 24515565.
Chavez Mac Gregor M, Liu S, De Melo-Gagliato D, Chen H, Do KA, Pusztai L, Fraser Symmans W, Nair L, Hortobagyi GN, Mills GB, Meric-Bernstam F, Gonzalez-Angulo AM. Differences in gene and protein expression and the effects of race/ethnicity on breast cancer subtypes. Cancer Epidemiol Biomarkers Prev 23(2):316-23, 2014. e-Pub 2013. PMID: 24296856.
Masuda H, Brewer TM, Liu DD, Iwamoto T, Shen Y, Hsu L, Willey JS, Gonzalez-Angulo AM, Chavez Mac Gregor M, Fouad TM, Woodward WA, Reuben JM, Valero V, Alvarez RH, Hortobagyi GN, Ueno NT. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes. Ann Oncol 25(2):384-91, 2014. e-Pub 2013. PMID: 24351399.
Shen MC, Massarweh NN, Lari SA, Vaporciyan AA, Selber JC, Mittendorf EA, Chavez Mac Gregor M, Smith BD, Kuerer HM. Clinical Course of Breast Cancer Patients with Isolated Sternal and Full-Thickness Chest Wall Recurrences Treated With and Without Radical Surgery. Ann Surg Oncol 20(13):4153-60, 2013. e-Pub 2013. PMID: 23959054.
Chavez Mac Gregor M, Zhang N, Buchholz TA, Zhang Y, Niu J, Elting L, Smith BD, Hortobagyi GN, Giordano SH. Trastuzumab-related cardiotoxicity among older patients with breast cancer. J Clin Oncol 31(33):4222-8, 2013. e-Pub 2013. PMID: 24127446.
Parinyanitikul N, Blumenschein GR, Wu Y, Lei X, Chavez Mac Gregor M, Smart M, Gonzalez-Angulo AM. Mesothelin expression and survival outcomes in triple receptor negative breast cancer. Clin Breast Cancer 13(5):378-84, 2013. e-Pub 2013. PMID: 23810431.
Chae YK, Hu MI, Katz RL, Chavez Mac Gregor M, Haluska P, Meric-Bernstam F, Gonzalez-Angulo AM, Melhem-Bertrandt A. Two birds with one stone: octreotide treatment for acromegaly and breast cancer. J Clin Oncol 31(23):e398-400, 2013. e-Pub 2013. PMID: 23796991.
Chavez Mac Gregor M, Clarke CA, Lichtensztajn D, Hortobagyi GN, Giordano SH. Male breast cancer according to tumor subtype and race: a population-based study. Cancer 119(9):1611-7, 2013. e-Pub 2013. PMID: 23341341.
Gonzalez-Angulo AM, Liu S, Chen H, Chavez Mac Gregor M, Sahin A, Hortobagyi GN, Mills GB, Do KA, Meric-Bernstam F. Functional proteomics characterization of residual breast cancer after neoadjuvant systemic chemotherapy. Ann Oncol 24(4):909-16, 2013. e-Pub 2012. PMID: 23139263.
Gonzalez-Angulo AM, Chen H, Karuturi MS, Chavez Mac Gregor M, Tsavachidis S, Meric-Bernstam F, Do KA, Hortobagyi GN, Thompson PA, Mills GB, Bondy ML, Blumenschein GR. Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer. Cancer 119(1):7-15, 2013. e-Pub 2012. PMID: 22736407.
Chae YK, Brown EN, Lei X, Melhem-Bertrandt A, Giordano SH, Litton JK, Hortobagyi GN, Gonzalez-Angulo AM, Chavez Mac Gregor M. Use of ACE Inhibitors and Angiotensin Receptor Blockers and Primary Breast Cancer Outcomes. J Cancer 4(7):549-56, 2013. e-Pub 2013. PMID: 23983819.
Krishnamurthy S, Woodward W, Yang W, Reuben JM, Tepperberg J, Ogura D, Niwa S, Huo L, Gong Y, El-Zein R, Gonzalez-Angulo AM, Chavez Mac Gregor M, Alvarez R, Lucci A, Valero V, Ueno NT. Status of the anaplastic lymphoma kinase (ALK) gene in inflammatory breast carcinoma. Springerplus 2:409, 2013. e-Pub 2013. PMID: 24156086.
Lynch SP, Lei X, Chavez Mac Gregor M, Hsu L, Meric-Bernstam F, Buchholz TA, Zhang A, Hortobagyi GN, Valero V, Gonzalez-Angulo AM. Multifocality and multicentricity in breast cancer and survival outcomes. Ann Oncol 23(12):3063-9, 2012. e-Pub 2012. PMID: 22776706.
Raghav KP, Wang W, Liu S, Chavez Mac Gregor M, Meng X, Hortobagyi GN, Mills GB, Meric-Bernstam F, Blumenschein GR, Gonzalez-Angulo AM. cMET and phospho-cMET protein levels in breast cancers and survival outcomes. Clin Cancer Res 18(8):2269-77, 2012. e-Pub 2012. PMID: 22374333.
Raghav KP, Hernandez-Aya LF, Lei X, Chavez Mac Gregor M, Meric-Bernstam F, Buchholz TA, Sahin A, Do KA, Hortobagyi GN, Gonzalez-Angulo AM. Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers. Cancer 118(6):1498-506, 2012. e-Pub 2011. PMID: 21837669.
Chavez Mac Gregor M, Brown E, Lei X, Litton J, Meric-Bernstram F, Mittendorf E, Hernandez L, Valero V, Hortobagyi GN, Gonzalez-Angulo AM. Bisphosphonates and pathologic complete response to taxane- and anthracycline-based neoadjuvant chemotherapy in patients with breast cancer. Cancer 118(2):326-32, 2012. PMID: 21590688.
Chavez Mac Gregor M, Zhao H, Kroll M, Fang S, Zhang N, Hortobagyi GN, Buchholz TA, Shih YC, Giordano SH. Risk factors and incidence of thromboembolic events (TEEs) in older men and women with breast cancer. Ann Oncol 22(11):2394-402, 2011. PMID: 21393379.
Theriault RL, Litton JK, Mittendorf EA, Chen H, Meric-Bernstam F, Chavez Mac Gregor M, Morrow PK, Woodward WA, Sahin A, Hortobagyi GN, Gonzalez-Angulo AM. Age and Survival Estimates in Patients Who Have Node-Negative T1ab Breast Cancer by Breast Cancer Subtype. Clin Breast Cancer 11(5):325-31, 2011. PMID: 21764391.
Chavez Mac Gregor M, Zhao H, Fang S, Srokowski TP, Hortobagyi GN, Giordano SH. Complications associated with erythropoietin-stimulating agents in patients with metastatic breast cancer: A Surveillance, Epidemiology, and End Results-Medicare Study. Cancer 117(16):3641-9, 2011. e-Pub 2011. PMID: 21656514.
Melhem-Bertrandt A, Chavez Mac Gregor M, Lei X, Brown EN, Lee RT, Meric-Bernstam F, Sood AK, Conzen SD, Hortobagyi GN, Gonzalez-Angulo AM. Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol 29(19):2645-52, 2011. e-Pub 2011. PMID: 21632501.
Hernandez-Aya LF, Chavez Mac Gregor M, Lei X, Meric-Bernstam F, Buchholz TA, Hsu L, Sahin AA, Do KA, Valero V, Hortobagyi GN, Gonzalez-Angulo AM. Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. J Clin Oncol 29(19):2628-34, 2011. e-Pub 2011. PMID: 21606433.
Chavez Mac Gregor M, Litton J, Chen H, Giordano SH, Hudis CA, Wolff AC, Valero V, Hortobagyi GN, Bondy ML, Gonzalez-Angulo AM. Pathologic complete response in breast cancer patients receiving anthracycline- and taxane-based neoadjuvant chemotherapy: evaluating the effect of race/ethnicity. Cancer 116(17):4168-77, 2010. PMID: 20564153.
Aft R, Naughton M, Trinkaus K, Watson M, Ylagan L, Chavez Mac Gregor M, Zhai J, Kuo S, Shannon W, Diemer K, Herrmann V, Dietz J, Ali A, Ellis M, Weiss P, Eberlein T, Ma C, Fracasso PM, Zoberi I, Taylor M, Gillanders W, Pluard T, Mortimer J, Weilbaecher K. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol 11(5):421-8, 2010. e-Pub 2010. PMID: 20362507.
Chavez Mac Gregor M, van Gils CH, van der Schouw YT, Monninkhof E, van Noord PA, Peeters PH. Lifetime cumulative number of menstrual cycles and serum sex hormone levels in postmenopausal women. Breast Cancer Res Treat 108(1):101-12, 2008. e-Pub 2007. PMID: 18274909.
Ruvalcaba-Limón E, Robles-Vidal C, Poitevin-Chacón A, Chavez Mac Gregor M, Gamboa-Vignolle C, Vilar-Compte D. Complications after breast cancer surgery in patients treated with concomitant preoperative chemoradiation: A case-control analysis. Breast Cancer Res Treat 95(2):147-52, 2006. e-Pub 2005. PMID: 16319989.
Chavez Mac Gregor M, Aviles-Salas A, Green D, Fuentes-Alburo A, Gómez-Ruiz C, Aguayo A. Angiogenesis in the bone marrow of patients with breast cancer. Clin Cancer Res 11(15):5396-400, 2005. PMID: 16061853.
Chavez Mac Gregor M, Elias SG, Onland-Moret NC, van der Schouw YT, Van Gils CH, Monninkhof E, Grobbee DE, Peeters PH. Postmenopausal breast cancer risk and cumulative number of menstrual cycles. Cancer Epidemiol Biomarkers Prev 14(4):799-804, 2005. PMID: 15824146.
Vidal-Millan S, Zeichner-Gancz I, Flores-Estrada D, Vela-Rodríguez BE, Vazquez-López MI, Robles-Vidal CD, Ramirez-Ugalde MT, Chavez Mac Gregor M. A descriptive study of second primary malignancies associated to breast cancer in a Mexican Hispanic population. Med Oncol 22(1):17-22, 2005. PMID: 15750192.

Invited Articles

Murthy RK, Chavez Mac Gregor M, Hortobagyi GN. Adjuvant HER2-Targeted Therapy Update in Breast Cancer: Escalation and De-escalation of Therapy in 2018. Curr Breast Cancer Reports(10):296-306, 2018.
Chaudry M, Banchs J, Chavez Mac Gregor M. Anthracycline or trastuzumab-related cardiotoxicity: do we have a predictive biomarker?. Biomark Med 10(3):315-28, 2016. e-Pub 2016. PMID: 26860187.
Bambhroliya A, Chavez Mac Gregor M, Brewster AM. Barriers to the Use of Breast Cancer Risk Reduction Therapies. J Natl Compr Canc Netw 13(7):927-35, 2015. PMID: 26150584.
Brewster AM, Chavez Mac Gregor M, Brown P. Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry. Lancet Oncol 15(13):e625-34, 2014. e-Pub 2014. PMID: 25456381.
Chavez Mac Gregor M, Gonzalez-Angulo AM. Breast cancer in 2012: New drugs, new knowledge, new targets. Nat Rev Clin Oncol 10(2):75-6, 2013. e-Pub 2013. PMID: 23296111.
Gagliato D, Chavez Mac Gregor M. Adjuvant bisphosphonates in breast cancer: has the time come?. Breast Cancer Manage 2(4):327-337, 2013.
Chavez Mac Gregor M, Gonzalez-Angulo AM. Everolimus in the treatment of hormone receptor-positive breast cancer. Expert Opin Investig Drugs 21(12):1835-43, 2012. e-Pub 2012. PMID: 22994502.
Chavez Mac Gregor M, González-Angulo AM. Breast cancer, neoadjuvant chemotherapy and residual disease. Clin Transl Oncol 12(7):461-7, 2010. PMID: 20615822.
Chavez Mac Gregor M, Gonzalez-Angulo AM. HER2-neu positivity in patients with small and node-negative breast cancer (pT1a,b,N0,M0): a high risk group?. Clin Adv Hematol Oncol 7(9):591-8, 2009. PMID: 20020671.
Ochoa-Carrillo FJ, Chavez Mac Gregor M, Green-Renner D, Green-Schneeweiss L. Paraneoplastic syndromes. Associated with lung cancer. Cir Cir 71(2):150-61, 2003. PMID: 19764144.
Chavez Mac Gregor M, Ochoa-Carrillo F, Fuentes-Alburo A. Neurological Paraneoplastic Syndromes. Rev Inst Nal Cancerol 46(4):281-289, 2000.

Editorials

Teshome M, Chavez Mac Gregor M. The Devastating Legacy of Breast Cancer Death in Sub-Saharan Africa-Maternal Orphans and a Cycle of Disadvantage. JAMA Oncol. PMID: 33355608.
de Melo Gagliato D, Chavez Mac Gregor M. Delays in Adjuvant Chemotherapy Among Breast Cancer Patients: An Unintended Consequence of Breast Surgery?. Ann Surg Oncol 25(7):1786-1787, 2018. PMID: 29600346.
Chavez Mac Gregor M, Mittendorf EA. Extended adjuvant therapy in patients with HER2-positive breast cancer: some answers, even more questions. Lancet Oncol 18(12):1568-1569, 2017. PMID: 29146400.
Mittendorf EA, Chavez Mac Gregor M. All HER2-Positive Tumors are not Created Equal. Ann Surg Oncol 24(12):3471-3474, 2017. PMID: 28815451.
Chavez Mac Gregor M, Giordano SH. Randomized Clinical Trials and Observational Studies: Is There a Battle?. J Clin Oncol 34(8):772-3, 2016. PMID: 26786920.
Chavez Mac Gregor M. Bone Therapy in Breast Cancer: Why, when and what's next?. The Breast Cancer Report 2(1), 2010.
Chavez Mac Gregor M, Gonzalez-Angulo AM. Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumors. Br J Cancer 100:680-83, 2009.
Chavez Mac Gregor M, Weilbaecher K, Aft R. Bone marrow micrometastases: Is there a role for bisphosphonates?. Breast Diseases: A Year Book Quarterly 19(4), 2009.

Abstracts

Chavez Mac Gregor M, Lei X, Tamirisa N, Caudle AS, Giordano SH. Re-excision rates among older breast cancer patients undergoing breast-conserving surgery (BCS): Impact of the SSO-ASTRO consensus guideline on margins. Poster Session: Breast Cancer - Local/ Regional / Adjuvant. 2020 ASCO Virtual Meeting, 2020.
Giordano SH, Liao K, Li L, Zorzi D, Chavez Mac Gregor M, Peterson SK. Patient reported outcomes in older breast cancer survivors. Poster Session: Symptoms and Survivorship. 2020 ASCO Virtual Meeting, 2020.
Smith-Graziani D, Lei X, Giordano SH, Zhao H, Karuturi M, Chavez Mac Gregor. Delayed initiation of adjuvant chemotherapy in older women with breast cancer. Poster Presentation. Arti Hurria Award in Geriatric Oncology award recipient. SABCS 2019, 2019.
Oke O, Niu J, Raghavendra A, Chavez Mac Gregor M, Zhao H, Tripathy D, Giordano SH. Palbociclib in advanced male hormone positive breast cancer. Poster Presentation. SABCS 2019, 2019.
Chavez Mac Gregor M, Lei X, Gagliato D, Valero V, Barcenas C, Hortobagyi GN, Giordano SH. Impact of delayed neoadjuvant systemic chemotherapy on survival among breast cancer patients. Poster Presentation. ESMO 30(Supplement 5), 2019.
Chavez Mac Gregor M. Outcomes associated with the use of bone-modifying agents (BMA) among older patients with metastatic breast cancer (BC). Poster Presentation. St. Gallen International Breast Cancer Conference, 2019.
Chavez Mac Gregor M. Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- everolimus in patients with high-risk, hormone receptor (HR) positive, HER2-negative breast cancer (BC): SWOG/NRG/Alliance S1207 (NCT01674140). Poster Presentation. St. Gallen International Breast Cancer Conference, 2019.
Ruiz R, Morante Z, Namuche F, Urrunaga D, Aguilar A, Schwarz J, Leon M, Ziegler G, Chavez Mac Gregor M, Gomez H. Evaluation of Oncotype DX testing and subsequent treatment choices in the Latin American setting. SABCS 2018, 2018.
Ruiz R, Morante Z, Namuche F, Urrunaga D, Leon M, Ziegler G, Aguilar A, Chavez Mac Gregor M, Gomez H. Clinicopathological characteristics associated with intermediate and high-risk ODx RS. SABCS 2018, 2018.
Chavez Mac Gregor M, Lei X, Zhao H, Bevers T, Brewster A, Giordano S. Impact of raloxifene adherence in breast cancer risk. SABCS 2018, 2018.
Murthy R, Raghavendra A, Hess K, Barcenas C, Lim B, Moulder S, Giordano S, Mittendorf E, Thompson A, Ueno N, Valero V, Litton J, Tripathy D, Chavez Mac Gregor M. 3-year relapse-free survival of stage II-III HER2-neu positive breast cancer treated with pertuzumab and trastuzumab-containing neoadjuvant therapy compared to trastuzumab-containing therapy. SABCS 2018, 2018.
Ruiz R, Namuche F, Morante Z, Aguilar A, Urrunaga D, Ziegler G, Chavez Mac Gregor M, Leon M, Gomez H. Age's importance in early breast cancer: Oncotype Dx results in patients ≤40 years. SABCS 2018, 2018.
Chavez Mac Gregor M. Use of bone-modifying agents (BMA) and osteonecrosis of the jaw (ONJ) among older patients with metastatic breast cancer (BC). Poster Session: Breast Cancer. ESMO 2018, 2018.
Chavez Mac Gregor M. Hepatitis B virus (HBV), Hepatitis C virus (HCV) and Human Immunodeficiency virus (HIV) screening prior to chemotherapy initiation among patients with solid tumors. Poster Session: Breast cancer. ESMO 2018, 2018.
Kehl KL, Chavez Mac Gregor M, Giordano SH, Schrag D. Historical non-treatment of metastatic non-small cell lung cancer: Implications for evaluating novel therapies. 2018 ASCO Annual Meeting, 2018.
Herrera Pena RA, Lei X, Chavez Mac Gregor M, Zhao H, Giordano SH, Suarez-Almazor ME. Overall survival in female Medicare beneficiaries with early stage breast cancer receiving bisphosphonates or denosumab. Poster Session: Breast Cancer - Local/Regional/Adjuvant. 2018 ASCO Annual Meeting, 2018.
Unger JM, Moseley A, Symington B, Chavez Mac Gregor M, Ramsey SD, Hershman DL. Geographic distribution and survival outcomes for rural cancer patients treated in clinical trials. Poster Session: Health Services Research, Clinical Informatics, and Quality of Care. 2018 ASCO Annual Meeting, 2018.
Oke O, Niu J, Chavez Mac Gregor M, Zhao H, Giordano SH. Adjuvant tamoxifen adherence in men with early stage breast cancer. Poster Session: Breast Cancer - Local/Regional/Adjunvant. 2018 ASCO Annual Meeting, 2018.
Zhao H, Lei X, Chavez Mac Gregor M, He W, Niu J, Giordano SH. Adherence to hormonal therapy among commercially insured breast cancer patients. Poster Session: Breast Cancer - Local/Regional/Adjuvant. 2018 ASCO Annual Meeting, 2018.
Al-Awadhi A, Lei X, Sanford RA, Valero V, Giordano SH, Chavez Mac Gregor M. Survival outcome of breast cancer (BC) patients presenting with recurrent and de novo isolated contralateral lymph node metastases (CLNM). Poster Session: Tumor Biology. 2018 ASCO Annual Meeting, 2018.
Bardia A, Modi S, Cortes J, Campone M, Dirix L, Ma B, Beck T, Chaves J, Weise A, Vuky J, Lopes G, Gil-Gil M, Liu X, He W, Su F, Miller M, Chavez Mac Gregor M. Baseline gene expression patterns of CDK4/6 inhibitor-naïve or -refractory HR+, HER2- advanced breast cancer in the phase Ib study of ribociclib plus everolimus plus exemestane. Poster Session: Phase I Clinical Trials 2. AACR 2018, 2018.
Giordano SH, Niu J, Zhao H, Zorzi D, Chavez Mac Gregor M. Association of body mass index (BMI) with chemotherapy administration and emergency room (ER) visits among breast cancer patients. Poster Session 6: Epidemiology, Risk, and Prevention: Epidemiology-population studies. SABCS 2017, 2017.
Chavez Mac Gregor M, Lei X, Morrow M, Giordano SH. Impact of the SSO-ASTRO consensus guidelines on invasive margins on the re-excision rate among patients undergoing breast conserving surgery (BCS). Poster Session 2: Treatment: Breast Conservation. SABCS 2017, 2017.
Murthy R, Raghavendra AS, Hogstrom KR, Zhang AH, Lim B, Barcenas CH, Chavez Mac Gregor M, Mittendorf EA, Litton JH, Giordano SH, Thompson A, Valero V, Tripathy D, Ueno N. Patterns of use and effectiveness of neoadjuvant pertuzumab-containing regimens in stage II-III HER2-neu positive breast cancer: A retrospective, single institutional experience. Poster Session 5: Treatment: Her2-targeted therapy. SABCS 2017, 2017.
Chavez Mac Gregor M, Lei X, Zhao H, Giordano SH. Determinants and outcomes associated with delays in adjuvant chemotherapy among breast cancer patients. ESMO 2017 28(5):51-52, 2017.
Weiss A, Chavez Mac Gregor M, Lichtensztajn D, Yi M, Clarke C, Giordano SH, Hunt K, Mittendorf E. Validation of the AJCC 8th edition prognostic stage in breast cancer. 2017 ASCO Annual Meeting, 2017.
Wong Y, Raghavendra A, Hatzis C, Irizarry J, Vega T, Barcenas C, Chavez Mac Gregor M, Valero V, Tripathy D, Pusztai L, Murthy R. Long-term survival of de novo stage IV human epidermal growth factor receptor 2 (HER2)-positive breast cancers treated with HER2 targeted therapy. 2017 ASCO Annual Meeting, 2017.
Oke O, Warneke C, Chavez Mac Gregor M, Milbourne A, Litton J. Outcomes related to delayed initiation of anti-HER 2 therapy in pregnant HER2 positive breast cancer patients. 2017 ASCO Annual Meeting, 2017.
Tadros A, Smith B, Shen Y, Lin H, Krishnamurthy S, Lucci A, Barcenas C, Hwang R, Rauch G, Santiago L, Strom E, DeSnyder S, Yang W, Black D, Albarracin C, Chavez Mac Gregor M, Hunt K, Kuerer H. Contemporary breast conservation patient outcomes for ductal carcinoma in situ and margins < 2 mm. 2017 ASCO Annual Meeting, 2017.
Hwang J, Suarez-Almazor M, Cantor S, Barbo A, Lin H, Ahmed S, Chavez Mac Gregor M, Donato-Santana C, Eng C, Ferrajoli A, Fisch M, McLaughlin P, Simon G, Rondon G, Shpall E, Lok A. Impact of the timing of hepatitis B virus (HBV) identification and anti-HBV therapy initiation on the risk of adverse liver outcomes in patients receiving cancer therapy. 2017 ASCO Annual Meeting, 2017.
Murthy R, Fujii T, Hess K, Raghavendra A, Lim B, Barcenas C, Zhang H, Chavez Mac Gregor M, Mittendorf E, Litton J, Giordano SH, Thompson A, Valero V, Tripathy D, Ueno N. Effect of neoadjuvant pertuzumab-containing regimens on pathologic complete response rates in stage II-III HER2-neu positive breast cancer: A retrospective, single institutional experience. 2017 ASCO Annual Meeting, 2017.
Wu X, Ye Y, Barcenas C, Chow W, Meng Q, Chavez Mac Gregor M, Hildebrant M, Zhao H, Gu Z, Deng Y, Wagar E, Esteva F, Tripathy D, Hortobadgy G. Personalized prognostic prediction models for breast cancer recurrence and survival incorporating multidimensional data. American Association for Cancer Research (AACR), 2017.
Juric D, Campone M, Munster P, Ismail-Khan R, Garcia L, Chavez Mac Gregor M, Frassoldati A, Hui R, Mayer I, Cortes J, Goncalves A, De Boer R, Dirix L, Tolaney S, Lee S, Maur M, Wang Y, Su Fm Dobson J, Germa C, Hewes B, Aditya B. Ribociclib + endocrine therapy (ET) doublet combinations in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advance breast cancer (ABC): Phase I clinical activity and impact of molecular alterations. American Association for Cancer Research (AACR), 2017.
Chavez Mac Gregor Mariana. The Next Era of Treatment for HR+/HER2– Advanced Breast Cancer: Clinical Trials of Endocrine Therapy + CDK4/6 Inhibitor + PI3K/AKT/mTOR Inhibitor Triplet Combinations. Miami Breast Cancer Conference 2017, 2017.
Chavez Mac Gregor M, Mittendorf EA, Clarke CA, Lichensztajn DY, Hunt KK, Giordano SH. Improving the AJCC breast cancer staging system by incorporating tumor biomarkers (P5-08-02). SABCS 2016, 2016.
Gallardo-Alvarado LN N, Cantu-De Leon DF F, Tusie-Luna T, Tusie-Luna I, Diaz-Chavez J, Herrera EM M, Chavez Mac Gregor M, Bargallo-Rocha E, Villarreal C, Herrera.Montalvo LA A and Segura-Kato YX. Li-Fraumeni syndrome in females with early onset breast cancer in a Mexican population (P2-02-04). SABCS 2016, 2016.
Kuerer HM M, Rauch GM M, Krishnamurthy S, Adrada BE E, Caudle AS S, DeSnyder SM M, Santiago L, Lucci A, Hobbs BP P, Gilcrease M, Hwang R, Candelaria RP P, Chavez Mac Gregor M, Arribas E, Moseley T, Teshome M, Miggins MV V, Smith BD D, Valero V, Hunt KK K and Yang WT T. Feasibility trial for identification of patients for eliminating breast cancer surgery following neoadjuvant systemic therapy (P5-16-30). SABCS 2016, 2016.
Mittendorf EA A, Vila J, Yi M, Chavez Mac Gregor M, Chen RL L, Giordano SH H and Hunt KK K. Evaluation of a risk score based on biologic factors to enhance prognostic stratification by the American Joint Committee on Cancer (AJCC) Staging System (P6-09-17). SABCS 2016, 2016.
Chavez Mac Gregor M, Zhigang D, Sharma M, Giordano SH. Everolimus use in breast cancer patients: a population-based study. Poster Session: Breast Cancer Metastatic (227PD). ESMO 2016, 2016.
Chavez Mac Gregor M, Lei X, Zhao H, Bevers T, Giordano SH, Brewster A. Use and adherence to breast cancer risk-reduction agents: A population-based study. Poster Session: Cancer Prevention, Genetics, and Epidemiology. Board #381. ASCO Annual Meeting 2016, 2016.
Sanford R, Lei X, Giordano SH, Tripathy D, Barcenas C, Chavez Mac Gregor M. Impact of delayed neoadjuvant systemic chemotherapy on survival outcomes in breast cancer patients. Poster Session: Breast Cancer—Triple-Negative/Cytotoxics/Local Therapy. Board #143. ASCO Annual Meeting 2016, 2016.
Giordano SH, Niu J, Chavez Mac Gregor M, Zhao H, Zorzi D, Shih YCT, Smith B, Shen C. Regimen-specific costs of chemotherapy for breast cancer (BC). Poster Discussion Session: Health Services Research and Quality of Care. Board #11. ASCO Annual Meeting 2016, 2016.
Barcenas C, Sinha A, Raghavendra A, Syed M, Hsu L, Patangan M, Chavez Mac Gregor M, Shen Y, Giordano SH, Ueno N, Valero V, Tripathy D.. Outcomes after chemotherapy in early-stage breast cancer (EBC) patients who underwent a 21-gene expression assay. Poster Session: Breast Cancer—HER2/ER. Board #47. ASCO Annual Meeting 2016, 2016.
Gallardo L, Tusie-Luna T, Tusie-Luna M, Diaz-Chavez J, Herrera Medina E, Chavez Mac Gregor M, Bargallo Rocha E, Segura Kato Yayoi, Villarreal C, Herrera Montalvo L, Cantu-de Leon D. TP53 germline mutations in young females with early onset breast cancer in a Mexican population. Category: Cancer Prevention, Hereditary Genetics, and Epidemiology. ASCO Annual Meeting 2016, 2016.
Chavez Mac Gregor M, Barlow WE, Pusztai L, Goetz MP, Rastogi P, Ganz PA, Mamounas EP, Paik S, Bandos H, Gralow J, Lew DL, Hortobagyi GN. Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of everolimus in patients with high-risk, hormone receptor (HR) positive and HER2-negative breast cancer (BC): SWOG/NRG/Alliance S1207 (NCT01674140). Session Info: Ongoing Clinical Trials: Ongoing Trials -- Targeted Therapies. SABCS 2015, 2015.
Chavez Mac Gregor M, Clark CA, Lichetensztajn DY, Giordano SH. Delayed initiation of adjuvant chemotherapy among breast cancer patients: A population-based study. Poster Session 1: Treatment: Adjuvant Chemotherapy. SABCS 2015, 2015.
Alvarez RH, Koenig KB, Ensor JE, Ibrahim NK, Chavez Mac Gregor M, Litton JK, Schwartz Gomez JK, Cyriac A, Krishnamurty S, Caudle AS, Shaitelman SF, Whitman GJ, Booser DJ, Reuben JM, Valero V. A randomized phase II neoadjuvant (NACT) study of sequential eribulin followed by FAC/FEC-regimen compared to sequential paclitaxel followed by FAC/FEC-regimen in patients (pts) with operable breast cancer not overexpressing HER-2. Poster Session 1: Treatment: Neoadjuvant Chemotherapy. SABCS 2015, 2015.
Basho RK, Gilcrease M, Murthy RK, Helgason T, Booser DJ, Karp DD, Meric-Bernstam F, Wheler JJ, Valero V, Albarracin C, Litton J, Chavez Mac Gregor M, Ibrahim NK, Murray JL, Koenig KB, Hong D, Subbiah V, Kurzrock R, Janku F, Moulder S. Targeting the PI3K/AKT/mTOR pathway for the treatment of mesenchymal triple-negative breast cancer (TNBC): Evidence of efficacy and proof of concept from a phase I trial with dose expansion of mTOR inhibition in combination with liposomal doxorubicin and bevacizumab. Poster Session 3: Treatment: Novel Targets and Targeted Agents. SABCS 2015, 2015.
Mittendorf EA, Vila J, Tucker SL, Chavez Mac Gregor M, Smith BD, Symmans WF, Sahin AA, Hortobagyi GN, Hunt KK. Bioscore: A novel staging system for breast cancer patients receiving neoadjuvant chemotherapy. Poster Session 5: Prognostic and Predictive Factors: Prognostic and Predictive Factors -- Other. SABCS 2015, 2015.
Bardia A, Modi S, Oliveira M, Campone M, Ma B, Dirix L, Weise A, Nardi L, Zhang V, Bhansali SG, Hewes B, Chavez Mac Gregor M. Triplet therapy with ribociclib, everolimus, and exemestane in women with HR+/HER2– advanced breast cancer. Poster Session 6: Treatment: New Drugs and Treatment Strategies. SABCS 2015, 2015.
Chavez Mac Gregor M, Lei X, Tripathy D, Rosenstock A, Giordano SH. Short-term mortality in older (>66) patients with early stage breast cancer treated with adjuvant chemotherapy. Poster Session: Cancer in the Elderly. 18^th ECCO - 40^th ESMO European Cancer Congress, 2015.
Chavez Mac Gregor M, Zhigang D, Hwang J, Giordano SH. Hepatitis B virus screening among Rituximab-treated patients. Poster Session: Haematological Malignancies. 18^th ECCO - 40^th ESMO European Cancer Congress, 2015.
Chavez Mac Gregor M, He W, Zhao H, Elting L, Giordano S. Antiemesis Prophylaxis among breast cancer (BC) patients receiving anthracycline-based chemotherapy: A population-based study. (Presented as an oral session at the 2015 Annual Meeting of the Multinational Association of Supportive Care in Cancer. Awarded Young Investigator Award). Support Care Cancer 2015; 23(s1) Journal of Supportive Care (#11-02-O), 2015.
Chavez Mac Gregor M, He W, Zhao H, Elting L, Giordano S. Antiemesis prophylaxis among breast cancer (BC) patients receiving highly emetogenic chemotherapy. ASCO Annual Meeting 2015 33, 2015.
Chavez Mac Gregor M, Barlow W, Gonzalez-Angulo A, Rastogi P, Mamounas E, Ganz P, Schott A, Paik S, Lew D, Bandos H, Hortobagyi G. Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of everolimus in patients with high-risk, hormone receptor (HR) positive and HER2-negative breast cancer (BC): SWOG/NRG/Alliance S1207 (NCT01674140). ASCO Annual Meeting 2015 33, 2015.
Sanford R, Lei X, Barcenas C, Mittendorf E, Caudle A, Valero V, Tripathy D, Giordano S, Chavez Mac Gregor M. Impact of neoadjuvant chemotherapy to surgery interval on survival outcomes in breast cancer patients. ASCO Annual Meeting 2015 33, 2015.
Barcenas C, Sinha A, Hortobagyi G, Valero V, Ueno N, Giordano S, Chavez Mac Gregor, Brewster A, Lucci A, Tripathy D. Hormonal treatment (HT) and late recurrence in early-stage breast cancer (BC) patients. ASCO Annual Meeting 2015 33, 2015.
Vila J, Bassett R, Mittendorf E, Bedrosian I, Shaitelman S, Stauder M, Chavez Mac Gregor M, Litton J, Yang W, Huo L, Kuerer H, Hunt K, Caudle A. A nomogram to predict axillary response to neoadjuvant chemotherapy in clinically node positive breast patients. ASCO Annual Meeting 2015, 2015.
DU FL, Fujii T, Davis D, Wu W, Jackson S, Chavez Mac Gregor M, Barcenas C, Murray J, Valero V, Tripathy D, Reuben J, Ueno N. EpCAM-independent isolation of EMT- circulating tumor cells in patients with primary breast cancer who receive primary systemic therapy. ASCO Annual Meeting 2015 33, 2015.
Basho R, Gagliato D, Ueno N, Alvarez R, Wathoo C, Chen H, Wei C, Sahin A, Roy-Chowdhuri S, Moulder S, Chavez Mac Gregor M, Litton J, Valero V, Luthra R, Shaw K, Mendelsohn J, Mills G, Tripathy D, Meric-Bernstam F. Clinical outcomes based on multigene profiling in metastatic breast cancer patients. ASCO Annual Meeting 2015 33, 2015.
Le Du F, Duose DY, Dettman EJ, Summer JA, Chavez Mac Gregor M, Barcenas CH, Brewster AM, Ricardo AH, Valero V, Gonzalez-Angulo AM, Reuben JM, Ueno NT. Predictive Impact of Circulating Tumor Cells with an Epithelial-To-Mesenchymal Transition Phenotype in Patients with Primary Breast Cancer Treated with Primary Systemic Therapy. Poster Session: Circulating Tumor Cells (P4-01-10). 2014 San Antonio Breast Cancer Symposium, 2014.
Rosenstock AS, Giordano SH, Niu J, Zhao H, Wolff AC, Buchholz TA, Chavez Mac Gregor M. AML and MDS after Adjuvant Chemotherapy: A Population Based Study among Older Breast Cancer Patients. Poster Session: Adjuvant Chemotherapy (P3-09-04). 2014 San Antonio Breast Cancer Symposium, 2014.
Chavez Mac Gregor M, Niu J, Smith B, Zhao H, Buchholz TA, Giordano SH. Oncotype Dx Use and its Relationship with Chemotherapy Administration in the General Population. Poster Session: Epidemiology-Population Studies (P3-07-05). 2014 San Antonio Breast Cancer Symposium, 2014.
Alvarez RH, Chavez Mac Gregor M, Ensor J, Murray JL, Koenig K, Krishnamurty S, Lucci A, Babiera GV, Woodward W, Whitman GJ, Jackson SA, Shi M, Culver K, Reuben JL, Ueno NT, Valero V. A Phase II Study of Dovitinib as Salvage Therapy in Patients with Stage IV Inflammatory Breast Cancer HER2-Negative with Local or Distant Relapse. Ongoing Clinical Trials 1: Targeted Therapies (OT1-1-15). 2014 San Antonio Breast Cancer Symposium, 2014.
Alvarez RH, Ibrahim NK, Ensor J, Koenig K, Chavez Mac Gregor M, Gonzalez-Angulo AM, Schwartz Gomez J, Madrigal AG, Krishnamurty S, Caudle AS, Shaitelman SF, Whitman GJ, Murray LJ, Booser DJ, Cox D, Reuben JM, Valero V. A Randomized Phase II Neoadjuvant Study of Sequential Eribulin Followed by FAC/FEC-Regimen Compared to Sequential Paclitaxel Followed by FAC/FEC-Regimen in Patients with Operable Breast Cancer not Overexpressing HER-2. Ongoing Clinical Trials 2: Chemotherapies (OT2-2-04). 2014 San Antonio Breast Cancer Symposium, 2014.
Liu D, Shen Y, Ueno NT, Alvarez RH, Chavez Mac Gregor M, Woodward WA, Kogawa T, Babiera G. Factors influencing survival in inflammatory breast cancer. J Clin Oncol 32(26_suppl):136, 2014. PMID: 28141031.
Chavez Mac Gregor M, Parinyanitikul N, Mittendorf EA, Lei X, Zhang H, Buzdar A, Hunt K, Hortobagyi GN, Valero V, Gonzalez-Angulo AM. Effect of Adjuvant Trastuzumab (T) Among Patients Treated with Neoadjuvant T-based Chemotherapy. J Clin Oncol 32(5), 2014.
Bardia A, Modi S, Chavez Mac Gregor M, Kittaneh M, Marino AJ, Matano A, Bhansali S, Hewes B, Cortes J. Phase Ib/II Study of LEE011, Everolimus, and Exemestane in Postmenopausal Women with ER+/HER2-Metastatic Breast Cancer. J Clin Oncol 32(5), 2014.
Kogawa T, Fouad TM, Wei C, El-Zein RA, Masuda H, Chavez Mac Gregor M, Melhem-Bertrandt A, Litton JK, Brewster AM, Alvarez RH, Hortobagyi GN, Vicente V, Ueno NT, Theriault RL. Association between body mass index change during neoadjuvant chemotherapy and pathologic complete response and overall survival in patients with inflammatory breast cancer or locally advanced non-inflammatory breast cancer. Proceedings from 2013 San Antonio Breast Cancer Symposium, 2013.
Chavez Mac Gregor M, Lei X, Litton JK, Melhem-Bertrand A, Giordano SH, Masuda H, Ueno N, Gabriel HN, Valero V. Statin use and outcome among breast cancer patients treated with neoadjuvant systemic chemotherapy. Proceedings from 2013 San Antonio Breast Cancer Symposium, 2013.
Masuda H, Chavez Mac Gregor M, Liu DD, Alvarez RH, Krishnamurthy S, Lucci A, Woodward W, Gildy B, Mittendorf EA, DeSnyder SM, Shen Y, Willey JS, Hortobagyi GN, Valero V, Ueno NT. Predictors of poor clinical outcome among patients with inflammatory breast cancer (IBC) who did and did not achieve pathological complete response (pCR) after neoadjuvant systemic chemotherapy. Proceedings from 2013 San Antonio Breast Cancer Symposium, 2013.
Fouad TM, Kogawa T, Liu DD, Shen Y, Masuda H, El-Zein R, Woodward WA, Arun B, Chavez Mac Gregor M, Alvarez RH, Lucci A, Krishnamurthy S, Hortobagyi GN, Valero V, Ueno NT. Survival difference between patients with metastatic inflammatory and non-inflammatory breast cancer. Proceedings from 2013 San Antonio Breast Cancer Symposium, 2013.
Lei X, Chavez Mac Gregor M, Mittendorf EA, Litton JK, Woodward WA, Zhang H, Hortobagyi GN, Gonzalez-Angulo AM. Receptor status change from primary to residual breast cancer after neoadjuvant chemotherapy (NCT) and analysis of survival outcome. J Clin Oncol 31(26_suppl):48, 2013. PMID: 28136644.
Gagliato DD, Gonzalez-Angulo AM, Aiudong L, Giordano SH, Theriault RL, Valero V, Hortobagyi GN, Chavez Mac Gregor M. Impact of delaying initiation of adjuvant chemotherapy in breast cancer patients. J Clin Oncol 31, 2013.
Chavez Mac Gregor M, Barlow WE, Gonzalez-Angulo AM, Rastogi P, Mamounas EP, Ganz PA, Schott A, Paik S, Lew D, Bandos H, Hortobagyi GN. Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy with or without one year of everolimus in patients with high-risk, hormone receptor- (HR) positive and HER2-neu-negative breast cancer: SWOG/NSABP S1207. J Clin Oncol 31, 2013.
Parinyanitikul N, Blumenschein GR, Wu Y, Lei X, Chavez Mac Gregor M, Smart ML, Gonzalez-Angulo AM. Mesothelin expression and survival outcomes in triple-receptor negative breast cancer. J Clin Oncol, 2013.
Pusztai L, Mattair D, Ueno NT, Valero V, Moulder SL, Murray JL, Alvarez RH, Chavez Mac Gregor M, Santiago L, Avritscher R, Sahin AA, Hortobagyi GN, Symmand WF, Meric-Bernstam F, Burton EM, Gonzalez-Angulo AM. Breast cancer evaluation and targeted investigational therapy (BEAT-IT): A pilot prospective tissue testing to guide clinical trial selection. J Clin Oncol(31), 2013.
Chavez Mac Gregor M, Zhang N, Niu J, Elting LS, Buchholz TA, Valero V, Giordano SH. Cardiac monitoring during adjuvant trastuzumab-based chemotherapy among older breast cancer patients. JClin Oncol 31, 2013.
Chavez Mac Gregor M, Parinyanitikul N, Lei X, Mittendorf E, Litton JK, Woodward W, Zhang A; Gonzalez-Angulo AM. Changes in breast cancer subtype between primary tumor and residual disease after neoadjuvant systemic chemotherapy. Proceedings from European CanCer Organization (ECCO) – ESMO Meeting, 2013.
Kogawa T, Fouad T, Liu D, Shen Y, Masuda H, Chavez Mac Gregor M, Alvarez RH, Valero V, Hortobagyi GN, Ueno NT. Role of HER2 FISH ratios in predicting pathological complete response (pCR) to neoadjuvant systemic chemotherapy with trastuzumab in patients with inflammatory breast cancer (IBC) and non-inflammatory locally advanced breast cancer. Proceeding from European CanCer Organization (ECCO) – ESMO Meeting, 2013.
Young Kwang C, Brown EN, Lei X. Melhem-Bertrandt A, Giordano SH, Litton JK, Hortobagyi GN, Gonzalez-Angulo AM, Chavez Mac Gregor M. ACE inhibitors and angiotensin receptor blockers use and breast cancer outcomes in patients treated with neoadjuvant systemic chemotherapy. J Clin Oncol 30, 2012.
Lynch SP, Lei X, Chavez Mac Gregor M, Hsu L, Meric-Bernstam F, Buchholz TA, Zhang H, Hortobagyi GN, Valero V, Gonzalez-Angulo AM. Breast cancer multifocality-multicentricity and survival outcomes. J Clin Oncol 30, 2012.
Chavez Mac Gregor M, Zhang N, Buchholz TA, Zhang Y, Niu J, Elting LS, Hortobagyi GN, Giordano SH. Trastuzumab-related cardiotoxicity among older breast cancer patients. J Clin Oncol 30 (#600), 2012.
Chavez Mac Gregor M, Lei X, Giordano SH, Valero V, Esteva F, Mittendorf EA, Gonzalez-Angulo AM, Hortobagyi GN. Predictors of long-term survival in a large cohort of patients with HER2-positive metastatic breast cancer. Cancer Res 72(24), 2012.
Chavez Mac Gregor M, Barlow WE, Gonzalez-Angulo AM, Rastogi P, Mamounas EP, Ganz PA, Schott AF, Paik S, Lew DL, Bandos H, Hortobagyi GN. A phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of everolimus in patients with high-risk, hormone receptor-(HR) positive and HER2-negative breast cancer: SWOG S1207. Cancer Res 72(24):570s (OT2-2-04), 2012.
Raghav KP, Wang W, Liu S, Chavez Mac Gregor M, Meng X, Hortobagyi GN, Mills GB, Meric-Bernstam F, Blimenschein GR, Gonzalez-Angulo AM. Expressions of c-met and phospho c-met in breast cancer by subtype and its impact on survival outcomes. Cancer Res 71(24), 2011.
Chavez Mac Gregor M, Clarke CA, Lichtensztajn DY, Hortobagyi GN, Giordano SH. Male breast cancer according to tumor subtype and race: A California cancer registry (ccr)-population based study. Cancer Res 71(24), 2011.
Chavez Mac Gregor M, Liu S, Chen H, Do K, Pusztai L, Symmans WF, Hortobagyi GN, Mills GB, Meric-Bernstam F, Gonzalez-Angulo AM. Relationship between differences in RNA or protein expression and the effects of race/ethnicity on breast cancer outcomes. 2011 Breast Cancer Symposium, 2011.
Chavez Mac Gregor M, Lei X, Litton JK, Melhem A, Mittendorf EA, Meric-Berstam F, Sahin AA, Valero V, Hortobagyi GN, Gonzalez-Angulo AM. Predictors of recurrence among patients with breast cancer who achieved a pathologic complete response (pCR) after neoadjuvant systemic chemotherapy. J Clin Oncol, 2011.
Raghav KPS, Hernandez-Aya LF, Lei X, Chavez Mac Gregor M, Meric-Bernstam F, Buchholz TA, Sahin AA, Do K, Hortobagyi GN, Gonzalez-Angulo AM. Impact of low estrogen and progesterone-receptor expression on survival outcomes in breast cancer previously classified as triple-negative breast cancers. J Clin Oncol 29(15s):85s, 2011.
Moulder S, Moroney J, Wheler J, Chavez Mac Gregor M, Helgason T, Booser D, Albarracin C, Morrow P, Koenig K, Kurzrock R. Responses to liposomal doxorubicin, bevacizumab and temsirolimus in patients with metastatic metaplastic breast cancer: implications for stem cell research in breast cancer. Annals of Oncology 22(2):55, 2011.
Chavez Mac Gregor M, Hubbard R, Meric-Bernstam F, Shinde SS, Litton JK, Woodard WA, Valero V, Hortobagyi GN, Symmans WF, Gonzalez-Angulo AM. Residual cancer burden (RCB) in breast cancer patients treated with taxane and anthracycline-based neoadjuvant chemotherapy: The effect of race. J Clin Oncol 28(15s), 2010.
Chavez Mac Gregor M, Zhao H, Kroll M, Fang S, Zhang N, Hortobagyi GN, Buchholz TA, Shih YCT, Giordano SH. Thromboembolic events in male breast cancer patients: A SEER-Medicare study. Proc of the Am Soc of Clin Oncol 2010 Breast Cancer Symposium, 2010.
Chavez Mac Gregor M, Zhao H, Hortobagyi GN, Giordano SH. Risk factors and incidence of thromboembolic events (TEE) in older patients after the diagnosis of breast cancer. Proc of the 5th Inter-American Breast Cancer Conference, 2010.
Chavez Mac Gregor M, Brown EN, Lei X, Hsu L, Meric-Bernstam F, Litton JK, Mittendorf EA, Valero V, Hortobagyi GN, Gonzalez-Angulo AM. Bisphosphonates and pathologic complete response to neoadjuvant chemotherapy in patients with breast cancer. Cancer Res 70(24s), 2010.
Litton JK, Chen H, Mittendorf EA, Meric-Bernstam F, Chavez Mac Gregor M, Woodward WA, Sahin A, Theriault RL, Hortobagyi GN, Gonzalez-Angulo AM. Outcome differences in tumors < 1cm by age and breast cancer subtype. J Clin Oncol, 2010.
Guarneri V, Chavez Mac Gregor M, Hsu L, Symmans WF, Litton JL, Mittendorf EA, Conte PF, Hortobagyi GN, Gonzalez-Angulo AM. Use of ki-67 in residual disease following preoperative chemotherapy to predict of recurrence and death in breast cancer patients. J Clin Oncol, 2010.
Chavez Mac Gregor M, Fang S, Zhao H, Hortobagyi GN, Giordano SH. Thromboembolic events in patient with breast cancer: A population based study. Caner Res 69(24):609s, 2009.
Chavez Mac Gregor M, Fang S, Srokowski TP, Hortobagyi GN, Giordano SH. Complications associated with erythropoietin stimulating agents (ESAs) in patients with metastatic breast cancer: A surveillance, epidemiology, and end results (SEER)-Medicare study. J Clin Oncol 27(15s), 2009.
Chavez Mac Gregor M, Litton J, Huiquin C, Meric-Bernstam F, Hudis CA, Wolff A, Valero V, Hortobagyi GN, Bondy ML, Gonzalez-Angulo A. Race and pathological complete response (pCR) in breast cancer patients receiving anthracycline and taxane-based neoadjuvant chemotherapy. 2009 Breast Cancer Symposium, 2009.
Chavez Mac Gregor M, Vranas P, Lara JM, Jackson SA, Willey JS, Hsu L, Ueno NT, Andreopoulou E, Valero V, Lucci A, Buzdar AU, Buchholz D, Hortobagyi GN, Cristofanilli M. Clinical outcomes in two different cohorts of patients with inflammatory breast cancer (IBC) treated at the MD Anderson Cancer Center: The experience of the Morgan Welch IBC Research Program and Clinic. Cancer Res, 2009.
Aft R, Watson M, Ylagan L, Chavez Mac Gregor M, Trinkaus K, Zhai J, Naughton M, Weilbaecher K. Effect of zoledronic acid on bone marrow micrometastases in women undergoing neoadjuvant chemotherapy for breast cancer. J Clin Oncol, 2008.

Book Chapters

Smith-Graziani, Chavez Mac Gregor M. Early Stage and Locally Advanced Breast Cancer. In: The MD Anderson Manual of Medical Oncology, Fourth Edition 4th Edition. 4th Edition. The MD Anderson Manual of Medical Oncology, 2021.
Karuturi M, Valero V, Chavez Mac Gregor M. Metastatic breast cancer. In: The MD Anderson Manual of Medical Oncology. 3rd Edition. McGraw Hill, 573-97, 2016.
Chavez Mac Gregor M, Hortobagyi GN. Metastatic breast cancer: A curable disease?. In: Breast Cancer Today. FEMA: Spain, 373-90, 2012.
Chavez Mac Gregor M, Valero V, Hortobagyi GN. Locally advanced breast cancer. In: Advanced Therapy of Breast Diseases. 3^rd Edition, 855-876, 2012.
Chavez Mac Gregor M, Gonzalez-Angulo AM. Metastatic Breast Cancer. In: Clinical Decision Support: Oncology, Digital Program, 2012.
Chavez Mac Gregor M, Gonzalez-Angulo AM, Hortobagyi GN. Breast Cancer Medical Therapy in High-Resource Countries. In: World Breast Cancer 2012. International Prevention Research Institute: France, 435-47, 2012.
Chavez Mac Gregor M, Valero V. Metastatic breast cancer. In: The MD Anderson Manual of Medical Oncology, 679-710, 2011.
Chavez Mac Gregor M, Wildes TM. Breast cancer. In: Hematology and Oncology Subspecialty Consult, The Washington Manual Subspecialty Consult Series. 2^nd edition, 189-203, 2008.

Letters to the Editor

Litton J, Buzdar A, Chavez Mac Gregor M, Gonzalez-Angulo A, Hortobagyi G. Tamoxifen therapy for patients with breast cancer. Lancet 381: 2077-8, 2013.

Less

Grant & Contract Support

Title:	Toxicities of Breast Cancer Treatment
Funding Source:	Susan G. Komen Breast Cancer Foundation
Role:	Co-Investigator

Title:	Comparative Effectiveness Research on Cancer in Texas (CERCIT) 2.0: Project 2
Funding Source:	Cancer Prevention Research Institute of Texas (CPRIT) Subcontract with UT Medical Branch - Galveston
Role:	Co-Investigator

Title:	Understanding barriers and decreasing the time to chemotherapy in a vulnerable population: Pilot study of a targeted intervention
Funding Source:	Conquer Cancer Foundation of the American Society of Clinical Oncology
Role:	Principal Investigator

CV information above last modified August 28, 2024

Mariana Chavez Mac Gregor, M.D., MSC

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Board Certifications

Experience & Service

Academic Appointments

Other Appointments/Responsibilities

Institutional Committee Activities

Honors & Awards

Professional Memberships

Selected Publications

Peer-Reviewed Articles

Invited Articles

Editorials

Abstracts

Book Chapters

Letters to the Editor

Grant & Contract Support

Patient Reviews

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Help #EndCancer

Mariana Chavez Mac Gregor, M.D., MSC

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Board Certifications

Experience & Service

Academic Appointments

Other Appointments/Responsibilities

Institutional Committee Activities

Honors & Awards

Professional Memberships

Selected Publications

Peer-Reviewed Articles

Invited Articles

Editorials

Abstracts

Book Chapters

Letters to the Editor

Grant & Contract Support

Patient Reviews

Request an Appointment

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Volunteer